Impact of COVID-19 on Liver Enzymes

COVID-19 can attack the liver due to the expression of Angiotensin-converting enzyme – 2 receptors on cholangiocytes. A cross-sectional study was conducted to determine the presence of deranged liver enzymes in COVID-19 patients. A total of 900 COVID-19 positive patients were included.


The mean age of participants was 46±07 years among which 52.2% were males and 47.8% were females. At admission, CRP value, mean SaO2 value, temperature, respiratory rate, and LDH were 110.7±14.3 mg/dL, 88.2±4.3%, 100.6±0.7oF, 30.6±4.9 BPM, and 325.6±87.5 IU respectively. The blood sample was collected and tested for C-reactive protein (CRP), lactate dehydrogenase LDH, and liver enzymes.


The study data showed that 28.2% of the participants had a minimum of one deranged liver enzyme. ALT was the most common deranged enzyme, both in males (19.9%) and females (21.3%), followed by AST (males: 18.3% and females: 20.3%) and serum GGT (males: 16.4% and females: 15.9%). Serum bilirubin was equally deranged in both genders (males: 8.4% and females: 8.3%). There was no significant difference in the prevalence of deranged liver enzymes between males and females.


Thus it can be concluded that liver enzymes are frequently deranged in COVID-19 patients. Therefore, liver enzymes should be regularly monitored in COVID-19 patients for better management of disease as various medications used in the treatment of COVID-19 may further deteriorate liver enzymes and may cause long-term damage. Further studies are required to confirm the findings of the study.


Source: Cureus


 

All About COVID-19 For Your Patients

WhiteCoats Insights For Your Practice



Join Thousands of Doctors who Trust WhiteCoats as their Professional Success Partner


For more queries, Call +91-7406-485-000 or mail us at sales@whitecoats.com


Download our App